Literature DB >> 8620339

Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease.

P N Hopkins1, L L Wu, S C Hunt, B C James, G M Vincent, R R Williams.   

Abstract

Mildly increased serum bilirubin has recently been suggested as a protective factor, possibly reducing the risk of coronary artery disease (CAD) by acting as an antioxidant. We tested this hypothesis by examining serum bilirubin concentrations and other coronary risk factors in 120 men and 41 women with early familial CAD and 155 control subjects. At screening, both cases and control subjects were 38 to 68 years old. Early familial CAD patients had experienced myocardial infarction, coronary artery bypass grafting, or coronary angioplasty by age 55 years for men and 65 for women and had another sibling similarly affected. The average total serum bilirubin concentration was 8.9 +/- 6.1 mumol/L in cases and 12.4 +/- 8.1 mumol/L in control subjects (P = .0001 for difference). In univariate analysis stratified by sex, serum bilirubin was strongly and inversely related to CAD risk, with relative odds of 0.4 to 0.1 (relative to the lowest quintile, P = .04 to .00001) in both men and women as bilirubin increased into the upper two quintiles. Multiple logistic regression analysis was performed including age, sex, smoking, body mass index, diabetes, hypertension, plasma measured LDL cholesterol, HDL cholesterol, triglycerides, and serum bilirubin as potential risk factors. Bilirubin entered as an independent protective factor with an odds ratio of 0.25 (P = .0015) for an increase of 17 mumol/L (1 mg/dL). The standardized logistic regression coefficient for bilirubin was -.33 compared with -.34 for HDL, suggesting that the protective effect of bilirubin on CAD risk in the population is comparable to that of HDL cholesterol. A history of cigarette smoking was associated with significantly lower serum bilirubin concentration and appeared to attenuate the protective effect of bilirubin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8620339     DOI: 10.1161/01.atv.16.2.250

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  78 in total

1.  Evidence for a gene influencing serum bilirubin on chromosome 2q telomere: a genomewide scan in the Framingham study.

Authors:  Jing-Ping Lin; L Adrienne Cupples; Peter W F Wilson; Nancy Heard-Costa; Christopher J O'Donnell
Journal:  Am J Hum Genet       Date:  2003-02-28       Impact factor: 11.025

2.  Induction of heme oxygenase-1 inhibits the monocyte transmigration induced by mildly oxidized LDL.

Authors:  K Ishikawa; M Navab; N Leitinger; A M Fogelman; A J Lusis
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 3.  Heme oxygenase, a novel target for the treatment of hypertension and obesity?

Authors:  Peter A Hosick; David E Stec
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-11-09       Impact factor: 3.619

4.  Preservation solution supplemented with biliverdin prevents lung cold ischaemia/reperfusion injury.

Authors:  Ryujiro Sugimoto; Yugo Tanaka; Kentaro Noda; Tomohiro Kawamura; Yoshiya Toyoda; Timothy R Billiar; Kenneth R McCurry; Atsunori Nakao
Journal:  Eur J Cardiothorac Surg       Date:  2012-05-30       Impact factor: 4.191

Review 5.  HO-1 overexpression and underexpression: Clinical implications.

Authors:  George S Drummond; Jeffrey Baum; Menachem Greenberg; David Lewis; Nader G Abraham
Journal:  Arch Biochem Biophys       Date:  2019-08-16       Impact factor: 4.013

6.  Serum bilirubin levels, UGT1A1 polymorphisms and risk for coronary artery disease.

Authors:  Arno Lingenhel; Barbara Kollerits; Johannes P Schwaiger; Steven C Hunt; Richard Gress; Paul N Hopkins; Veit Schoenborn; Iris M Heid; Florian Kronenberg
Journal:  Exp Gerontol       Date:  2008-08-26       Impact factor: 4.032

Review 7.  Wearable sensors: modalities, challenges, and prospects.

Authors:  J Heikenfeld; A Jajack; J Rogers; P Gutruf; L Tian; T Pan; R Li; M Khine; J Kim; J Wang; J Kim
Journal:  Lab Chip       Date:  2018-01-16       Impact factor: 6.799

8.  Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Authors:  K H Chan; R L O'Connell; D R Sullivan; L S Hoffmann; K Rajamani; M Whiting; M W Donoghoe; M Vanhala; A Hamer; B Yu; R Stocker; M K C Ng; A C Keech
Journal:  Diabetologia       Date:  2013-01-17       Impact factor: 10.122

9.  PharmGKB very important pharmacogene: SLCO1B1.

Authors:  Connie Oshiro; Lara Mangravite; Teri Klein; Russ Altman
Journal:  Pharmacogenet Genomics       Date:  2010-03       Impact factor: 2.089

Review 10.  Bilirubin, a Cardiometabolic Signaling Molecule.

Authors:  Terry D Hinds; David E Stec
Journal:  Hypertension       Date:  2018-10       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.